MRKMerck Sharp & Dohme LLCSigning up patients
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 770 (planned)
- Started
- Apr 9, 2025
- Main results expected
- Apr 27, 2029
- Fully finished
- Nov 9, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Number of Participants With One or More Adverse Events (AEs)
Measured over: Up to 6 weeks
Part 1: Number of Participants Who Discontinue Study Intervention Due to an AE
Measured over: Up to 6 weeks
Part 2: Progression-Free Survival (PFS)
Measured over: Up to approximately 4 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06824467 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC